IXHL
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. Its lead drug candidate, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide for the treatment of obstructive sleep apnea, which has received FDA Fast Track designation. The company is also developing PSX-001, an oral synthetic psilocybin treatment administered with psychological therapy for generalized anxiety disorder, and IHL-675A, a combination of cannabidiol and hydroxychloroquine sulfate for inflammatory conditions such as rheumatoid arthritis. Incannex targets the United States market initially, with plans to expand into the European Union, United Kingdom, Japan, Australia, and Canada following U.S. approval. The company utilizes FDA expedited review programs and the 505(b)(2) pathway to advance its pipeline.

Summarised from the company's own disclosures, fiscal year ended Sep 2026

Industry Biotechnology Homepage incannex.com
Sector Healthcare IR page incannex.com/investors
Tags
obstructive sleep apnea, generalized anxiety disorder, rheumatoid arthritis, cannabinoid-based medicines, psychedelic-assisted therapy, fixed-dose combinations, clinical-stage, oral therapies, IHL-42X, PSX-001, IHL-675A, RePOSA Study, DReAMzz Study, PsiGAD1, dronabinol, acetazolamide, synthetic psilocybin, cannabidiol, hydroxychloroquine sulfate
Press page —

Metrics

Valuation  
Market cap $ 40.645M
Market cap (USD) $ 40.645M
P/E -4.84
PEG —
P/BV 0.61
P/S 472.61
P/OCF -12.77
P/FCF -12.74
Dividend yield —
Turnover / mcap —
Returns  
ROE -47.8%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 53
Quality score -63.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 0 86K 12K — 414.095K 0
Net profit -19.302M -46.885M -18.459M -19.98M -14.904M 0
Free cash flow -12.877M -12.521M -16.122M -16.42M -8.81M —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 3.76 0.22 2.94 — — —
Price performance 12m 16.43 -0.93 — — — —

Filed figures

Figure Jun 2020 Jun 2021 Jun 2022 Dec 2022 Jun 2023 Dec 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Lease liabilities (USD) — — — — 521,000 470,000 373,000 258,000 96,000
Cash and deposits (USD) — — 25.8M 28.1M 22.1M 14.6M 5.86M 15M 67.7M
Right-of-use assets (USD) — — — — 492,000 468,000 373,000 258,000 97,000
Cash flow detail
Operating cash flow (USD) — — — — -10.7M — -15.8M -12.5M -12.9M
Purchases of property, plant and equipment (USD) — — — — -316,000 — -277,000 -8,000 -10,000
Change in payables (cash effect) (USD) — — — — — — 3.02M 1.39M -2.07M
Share buybacks (cash effect) (USD) — — — — — — — 0.00 -9.4M
Share-based compensation (USD) 565,448 600,043 1.46M — 2.15M — 8.93M 2.61M 7.56M
Free cash flow (OCF - PPE - intangibles) (USD) — — — — -11.1M — -16.1M -12.5M -12.9M
Income detail
Research and development expense (USD) 2.11M 4.75M 5.37M — 9.36M — 12.9M 10.7M 5.21M
↳ 5y CAGR +38.5% +1.9%
Total comprehensive income (USD) — — — 41.1M -51.1M 5.97M -18.5M -46.7M -19.8M
Comprehensive income to owners (USD) — — — 41.1M -51.1M 5.97M -18.5M -46.7M -19.8M
Reported Oct 28, 2022 Oct 28, 2022 Feb 14, 2024 Feb 14, 2024 Sep 30, 2024 Feb 14, 2024 Sep 29, 2025 Sep 25, 2026 Sep 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

September 9, 2026

PDF Version

  • Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea

  • U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040

  • Approximately $70 million in cash and no debt, including more than A$11.2 million in non-dilutive capital received during 2026

NEW YORK and MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today provides a corporate update reporting the dosing of the first patient in its DReAMzz Phase 2 study of IHL-42X in obstructive sleep apnea, the grant of a U.S. composition patent covering IHL-42X, and a cash position of approximately $70 million with no debt.

Incannex President and CEO Joel Latham stated, “The commencement of patient dosing in DReAMzz marks a key milestone in the clinical development of IHL-42X. The protocol, which was shaped by our clinical advisory board and incorporates feedback from the FDA, was designed to produce the dose-selection data we need to enter a Phase 3 registration program with confidence. The program is well protected, with the recently granted composition patent extending protection to 2040, and well funded by our healthy cash position.”

IHL-42X for Obstructive Sleep Apnea

On August 25, 2026, Incannex announced the commencement of patient dosing in DReAMzz, a Phase 2 crossover dose-optimization study of IHL-42X in patients with obstructive sleep apnea. The study is being conducted across 13 clinical trial sites in the United States, each of which has received Institutional Review Board approval.

DReAMzz is designed to refine the dosing profile of IHL-42X and to inform the design of a subsequent Phase 3 registration program. The study protocol was developed with input from the Company's Obstructive Sleep Apnea Clinical Advisory Board, comprising physicians and researchers in sleep medicine and respiratory disease, and was reviewed by the U.S. Food and Drug Administration, with agency feedback incorporated into the final design.

Incannex previously completed the RePOSA Phase 2 study, which enrolled 121 subjects across 16 sites in the United States and reported positive topline results in August 2025. Patients enrolled in RePOSA were non-compliant with, intolerant of, or naive to positive airway pressure therapy. Both the low-dose and high-dose IHL-42X groups demonstrated greater percentage reductions in the apnea-hypopnea index relative to baseline than placebo, and greater reductions in the oxygen desaturation index than placebo, in each case with statistical significance. Individual reductions in apnea-hypopnea index of up to 83 percent were observed. The FDA granted Fast Track designation to IHL-42X in December 2025.

PSX-001 for Generalized Anxiety Disorder

PSX-001, the Company’s oral synthetic psilocybin therapeutic, continues to advance as a differentiated potential treatment for generalized anxiety disorder (GAD), a significant and underserved mental health condition.

In August 2025, the Company reported positive topline results from the completed 73-subject PsiGAD1 Phase 2 study. These encouraging results provide a strong clinical foundation for the program’s next stage of development. The Company also has an open U.S. Investigational New Drug application for PsiGAD2, a Phase 2b dose-comparison study, supporting continued regulatory and clinical progress in the United States.

To sharpen PSX-001’s competitive positioning and expand its potential, the Company has assembled a clinical advisory board of leading experts in psychiatry, psychiatric drug development and mental health treatment. Working with these key opinion leaders, the Company has developed innovative strategies for advancing psilocybin-based therapies in GAD and other high-value mental health indications.

The Company has also presented a refined development strategy to the UK Medicines and Healthcare products Regulatory Agency (MHRA) through a scientific advice meeting. Feedback from the MHRA, combined with continued input from the clinical advisory board, is actively informing the program’s clinical and regulatory pathway.

With positive Phase 2 results, an open U.S. IND, regulatory engagement in the UK and guidance from internationally recognized experts, PSX-001 has multiple catalysts supporting its continued advancement. The Company believes these achievements strengthen the program’s differentiation and position PSX-001 to address substantial unmet patient need while creating meaningful long-term value for shareholders.

Intellectual Property

On June 25, 2026, the United States Patent and Trademark Office granted Incannex a patent titled, "Compositions and Methods of Treatment for Obstructive Sleep Apnea," with claims directed to the IHL-42X composition and associated methods of treatment. The patent carries a baseline expiry of July 9, 2040. The Company is evaluating eligibility for patent term extension in the event of future marketing approval.

Financial Position

As of 31 August 2026, Incannex held approximately $70 million in cash and cash equivalents and carried no debt.

During 2026, the Company received more than A$11.2 million in non-dilutive capital through the Australian Research and Development Tax Incentive program, comprising an A$6.0 million refund announced in June 2026 in respect of fiscal year 2025 and an additional A$5.1 million refund announced in August 2026.

About IHL-42X

IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide being developed for the treatment of obstructive sleep apnea. The two components act on distinct physiological processes associated with the condition. Dronabinol activates muscles in the upper airway and dampens afferent vagal feedback, stabilizing respiratory patterns and dilating the upper airway. Acetazolamide inhibits carbonic anhydrase, prompting respiratory drive at lower carbon dioxide levels. IHL-42X holds Fast Track designation from the U.S. Food and Drug Administration.

About PSX-001

PSX-001 is an oral synthetic psilocybin therapeutic being developed for the treatment of generalized anxiety disorder.

About Incannex Healthcare Inc.

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company's lead programs include IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the development, clinical performance, regulatory progress and potential commercialization of the Company’s drug candidates; the design, conduct, timing and anticipated outcomes of clinical trials; the potential benefits of regulatory designations; the Company’s intellectual property protection and potential patent term extension; the sufficiency of its capital resources; and potential shareholder value. Words such as “may,” “could,” “should,” “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “plan,” “potential,” “predict,” “project,” “will,” “would” and similar expressions identify forward-looking statements.

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These include the risks that clinical trials may be delayed, may not meet their endpoints or may identify safety concerns; earlier clinical results may not predict later outcomes; regulatory authorities may require additional studies or may delay or deny approval; regulatory feedback and Fast Track designation may not result in an accelerated or successful approval pathway; and the Company may experience difficulties with patient enrollment, clinical sites, contractors or manufacturing. Intellectual property risks include the possibility that patents may be challenged, narrowed, invalidated, circumvented or found unenforceable; may not prevent competing products; may not provide protection in all relevant jurisdictions; or may not qualify for patent term extension. The Company may also face third-party intellectual property claims. Additional risks include the possibility that the Company’s cash resources may be used more quickly than anticipated and that additional financing may be required.

Other risks are described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and in its subsequent filings with the SEC, available at www.sec.gov. Readers should not place undue reliance on forward-looking statements, which speak only as of their date. Except as required by law, the Company undertakes no obligation to update them.

Investor & Media Contacts

CORE IR

(212) 655-0924

[email protected]

[email protected]

Investor & Media Contacts

drafts [email protected]

drafts [email protected]

Search Investors

August 25, 2026

PDF Version

First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation

NEW YORK and MELBOURNE, Australia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, the Company’s oral fixed-dose combination drug candidate for the treatment of obstructive sleep apnea (“OSA”). The milestone builds on the positive results from the Phase 2 RePOSA study, in which IHL-42X demonstrated statistically significant reductions in apnea-hypopnea index (“AHI”) compared with placebo, with individual reductions in AHI of up to 83% observed and exceptional safety profile.

First patient dosing represents another significant milestone in the continued advancement of IHL-42X and follows a period of substantial clinical and regulatory progress for the program. Over the past year, Incannex has reported positive Phase 2 RePOSA results, received Fast Track designation from the U.S. Food and Drug Administration (“FDA”), and advanced its regulatory strategy following engagement with the FDA. The company’s current focus, the DReAMzz dose-optimization study, recently commenced patient screening and has now progressed to active patient dosing. All 14 DReAMzz sites now have approval from the Institutional Review Board to conduct the study.

The DReAMzz study is designed to further optimize dose selection for IHL-42X and strengthen the clinical and regulatory foundation for the Company’s planned Phase 3 development program.

Joel Latham, President and Chief Executive Officer of Incannex, said:

“Dosing the first patient in DReAMzz is another important milestone for IHL-42X and continues a period of significant clinical and regulatory progress for the program.

“The momentum behind IHL-42X has continued to build over the past year. We delivered positive RePOSA results, including statistically significant reductions in AHI and individual reductions of up to 83%, secured FDA Fast Track designation, advanced our regulatory strategy and have now commenced patient dosing in DReAMzz.

“We believe IHL-42X has the potential to reshape the treatment landscape for obstructive sleep apnea. OSA affects hundreds of millions of people globally, yet there remains a significant need for an effective oral pharmaceutical treatment. The clinical results generated to date give us increasing confidence in the potential of IHL-42X to address that need.

“Our focus now is execution. DReAMzz is designed to optimize the treatment regimen and provide the data required to advance IHL-42X toward Phase 3 development. With strong clinical data, FDA Fast Track designation and DReAMzz now actively dosing patients, we believe IHL-42X is exceptionally well positioned as we enter this next stage of development.”

FDA Fast Track Designation Supports Continued Development

The clinical progress of IHL-42X was further reinforced by the FDA granting Fast Track designation to the program.

Fast Track designation is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs. The designation provides opportunities for more frequent interactions with the FDA during development and, subject to applicable requirements, may provide access to mechanisms intended to accelerate regulatory review.

The designation was supported by the safety, efficacy and pharmacokinetic data generated across the IHL-42X clinical development program, including the positive results from the Phase 2 RePOSA study.

Incannex believes Fast Track designation, together with the clinical evidence generated to date, provides important regulatory support as the Company advances IHL-42X through dose optimization and toward Phase 3 development.

DReAMzz Phase 2 Dose-Optimization Study

DReAMzz is a Phase 2 crossover dose-optimization study designed to further characterize the dose-response profile of IHL-42X and inform dose selection for subsequent late-stage clinical development.

The study will evaluate objective sleep-related measures alongside patient-reported outcomes, providing additional data intended to refine the IHL-42X treatment regimen and strengthen the design of the Company’s planned Phase 3 program.

Incannex has established a network of 14 clinical trial sites across the United States to support execution of DReAMzz. Drug product has been manufactured, regulatory and operational preparations have been completed, clinical sites have commenced patient screening and the first patient has now been dosed.

About IHL-42X

IHL-42X is Incannex’s proprietary oral fixed-dose combination of dronabinol and acetazolamide being developed for the treatment of obstructive sleep apnea.

The combination is designed to target complementary physiological mechanisms implicated in OSA through a single oral pharmaceutical therapy.

IHL-42X has received Fast Track designation from the U.S. Food and Drug Administration.

About Incannex Healthcare Inc.

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s lead programs include IHL-42X for obstructive sleep apnea, IHL-675A for rheumatoid arthritis and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to management’s expectations regarding the development, regulatory progress and commercialization of the Company’s drug candidates, the potential value of the Company’s drug candidates and business, and potential shareholder value. When or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated, risks associated with the clinical development of IHL-42X and PSX-001, and other risks described in the section entitled “Risk Factors” described in the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor & Media Contacts

CORE IR (212) 655-0924 [email protected] [email protected]

Investor & Media Contacts

drafts [email protected]

drafts [email protected]

Search Investors

August 11, 2026

PDF Version

Completion of more than A$11.2 million in non-dilutive capital received under the Australian Government’s R&D Tax Incentive Program further strengthens Company’s balance sheet and financial flexibility

NEW YORK and MELBOURNE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, today announced it has received the final A$5,102,788.30 refund under the Australian Government’s Research and Development Tax Incentive Program following approval of the Company’s overseas findings and amendment of its FY25 income tax return.

Together with the previously announced A$6,039,162.43 refund, Incannex has now received more than A$11.2 million in non-dilutive capital during 2026. The receipt further enhances Incannex’s already strong cash position and debt-free balance sheet, providing additional financial flexibility to advance its clinical pipeline while continuing to pursue shareholder-focused capital allocation initiatives.

Highlights

  • Received the final A$5.1 million R&D Tax Incentive refund following approval of overseas findings, further strengthening the Company’s balance sheet with non-dilutive capital. Incannex expects to receive additional R&D Tax Incentive funding in 2027 in respect of eligible ongoing research and development activities.

  • The refund recognizes the significant eligible Australian research and development activities undertaken by the Company in developing therapeutic regimens designed to address challenging chronic conditions during the financial year ended 30 June 2025.

  • Total FY25 R&D Tax Incentive proceeds now exceed A$11.2 million

  • Entire amount received as non-dilutive capital, with no shareholder dilution

  • Further strengthens the Company’s already robust balance sheet and financial flexibility

  • Supports continued advancement of key clinical assets, including IHL-42X and PSX-001

  • Reinforces disciplined capital management and shareholder-focused capital allocation strategy

The Australian Government’s Research and Development Tax Incentive Program is designed to encourage innovation by providing eligible companies with cash refunds for qualifying research and development activities.

Following approval of the Company’s overseas findings, Incannex amended its FY25 income tax return, resulting in the additional refund announced today. This outcome reflects the Company’s successful execution of its strategy to maximize eligible R&D incentives while continuing to invest in the advancement of its clinical pipeline.

Importantly, these proceeds are entirely non-dilutive, enabling Incannex to recover a substantial portion of eligible research and development expenditure without issuing additional equity or taking on debt. At a time when many biotechnology companies continue to rely on dilutive capital raises to fund operations, the Company believes this outcome further differentiates the strength of its financial position and disciplined approach to capital management.

Joel Latham, President and Chief Executive Officer of Incannex Healthcare, commented:

“The receipt of this final refund completes more than A$11.2 million in non-dilutive capital received under the Australian Government’s Research and Development Tax Incentive Program and represents another significant achievement for Incannex and our shareholders.

“Combined with our existing cash position and debt-free balance sheet, this additional capital further enhances our financial flexibility as we continue advancing our late-stage clinical pipeline, including IHL-42X and PSX-001, while maintaining a strong focus on shareholder returns.

“We believe the market continues to significantly undervalue the strength of our balance sheet relative to our enterprise value. The completion of more than A$11.2 million in non-dilutive funding further reinforces our ability to execute on our strategy, fund the continued advancement of our clinical programs and pursue shareholder-focused capital allocation initiatives from a position of financial strength.”

About Incannex Healthcare Inc.

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s lead programs include IHL-42X for obstructive sleep apnea, IHL-675A for rheumatoid arthritis and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to management’s expectations regarding the development, regulatory progress and commercialization of the Company’s drug candidates, the potential value of the Company’s drug candidates and business, and potential shareholder value. When or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated, risks associated with the clinical development of IHL-42X and PSX-001, and other risks described in the section entitled “Risk Factors” described in the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor & Media Contacts

CORE IR (212) 655-0924 [email protected] [email protected]

Investor & Media Contacts

drafts [email protected]

drafts [email protected]

Search Investors

Prompts

Incannex Healthcare Inc. (ticker IXHL), listed in United States.

ETFs Holding Incannex Healthcare Inc.

ETF Weight in ETF Shares Market value As of
PSIL 0.71% 156,359 $ 272.065K Nov 17, 2026